Phase I study of the Bcl-2 inhibitor venetoclax with DA-EPOCH-R as initial therapy for aggressive B-cell lymphomas.
Sarah C. Rutherford(NewYork–Presbyterian Hospital), John P. Leonard(New York University), Stefan K. Barta(University of Pennsylvania), Jason R. Westin(The University of Texas MD Anderson Cancer Center), Kami J. Maddocks(The Ohio State University), Robin Joyce(Beth Israel Deaconess Medical Center), Jeremy S. Abramson(Massachusetts General Hospital), Silvia Senese(University of California, Los Angeles), Trisha Ali-Shaw(Cornell University), Nadia Khan(Fox Chase Cancer Center), Nancy L. Bartlett(Washington University in St. Louis), Ying Yuan(The University of Texas MD Anderson Cancer Center)
Cited by 8
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2018|2.3k
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
|New England Journal of Medicine|2021|1.6k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k